Ceruloplasmin as a Predictor for Responsiveness to Direct Antiviral Drugs in Treatment of Chronic HCV Infection
Hussein, M., Mahmoud, A., Ibrahim, A., Bakeer, M., Hussein, S., Mahmoud, A., Eldahshan, T. (2019). Ceruloplasmin as a Predictor for Responsiveness to Direct Antiviral Drugs in Treatment of Chronic HCV Infection. EKB Journal Management System, 75(1), 1963-1968. doi: 10.21608/ejhm.2019.29168
Mohammed Salah Hussein; Asem Ashraf Mahmoud; Abdel Rahman Ibrahim; Mohammed Saied Bakeer; Safaa Abd Elsalam Hussein; Abdelhalim Assem Mahmoud; Tarek Eldahshan. "Ceruloplasmin as a Predictor for Responsiveness to Direct Antiviral Drugs in Treatment of Chronic HCV Infection". EKB Journal Management System, 75, 1, 2019, 1963-1968. doi: 10.21608/ejhm.2019.29168
Hussein, M., Mahmoud, A., Ibrahim, A., Bakeer, M., Hussein, S., Mahmoud, A., Eldahshan, T. (2019). 'Ceruloplasmin as a Predictor for Responsiveness to Direct Antiviral Drugs in Treatment of Chronic HCV Infection', EKB Journal Management System, 75(1), pp. 1963-1968. doi: 10.21608/ejhm.2019.29168
Hussein, M., Mahmoud, A., Ibrahim, A., Bakeer, M., Hussein, S., Mahmoud, A., Eldahshan, T. Ceruloplasmin as a Predictor for Responsiveness to Direct Antiviral Drugs in Treatment of Chronic HCV Infection. EKB Journal Management System, 2019; 75(1): 1963-1968. doi: 10.21608/ejhm.2019.29168

Ceruloplasmin as a Predictor for Responsiveness to Direct Antiviral Drugs in Treatment of Chronic HCV Infection

The Egyptian Journal of Hospital Medicine
Article 9, Volume 75, Issue 1, April 2019, Page 1963-1968  XML PDF (766.83 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2019.29168
View on SCiNiTO View on SCiNiTO
Authors
Mohammed Salah Hussein email 1; Asem Ashraf Mahmoud2; Abdel Rahman Ibrahim3; Mohammed Saied Bakeer1; Safaa Abd Elsalam Hussein4; Abdelhalim Assem Mahmoud5; Tarek Eldahshan6
1Department of Internal Medicine, Faculty of Medicine, Al-Azhar University
2Department ofGastroenterology and Hepatology, Military Medical Academy
3Department of Internal Medicine,Algalaa Military Hospital
4Department of Internal Medicine, Faculty of Medicine, Ain Shams University
5Department of Tropical Medicine, Faculty of Medicine, Al-Azhar University
6Department of Clinical Pathology, Faculty of Medicine, Al-Azhar University
Abstract
Background: Hepatitis C virus (HCV) is one of the major globally cause of death and morbidity. The appearance of direct-acting antiviral agents (DAAs), which specifically target HCV proteins, has provided insights into the current situation Ceruloplasmin (Cp), where its serum levels tend to be high in myocardial infarction, neoplastic and inflammatory conditions. Objective: The aim of the current work was to evaluate the prognostic value of serum ceruloplasmin in chronic hepatitis C before and after treatment by direct-acting antiviral agents and possibility of using it as a marker for hepatitis C virus treatment response. Patients and methods: This intervention prospective study was conducted on one hundred subjects attending at the Hepatology Clinic at the Hepatology Clinic at Algalaa Military Hospital and Kopri Elkopa Military Hospital and Al-Hussein university Hospital, from December 2016 till June 2017. The associations between serum Ceruloplasmin levels in chronic HCV patients before receiving DAAS and three months after was investigated. Results: showed that serum Ceruloplasmin levels were slightly higher after receiving DAAS and so it can be used as a marker for responsiveness to direct acting antiviral drugs. Conclusion: It could be concluded that ceruloplasmin can be used as a marker for responsiveness to direct acting antiviral drugs
Keywords
Ceruloplasmin; Hepatitis C virus; Direct acting antiviral agents
Statistics
Article View: 242
PDF Download: 467